Regional expansion Oncopeptides is actively commercializing Pepaxti in Europe and has distribution partnerships planned or established for South Korea, the Middle East and Africa, signaling growth opportunities in these regions for sales outreach and new market entry discussions with distributors.

Clinical pipeline The company is developing multiple new drug candidates on its PDC and SPiKE platforms, presenting opportunities to cross-sell or co-develop with potential partners, while enabling a sales argument around expanded therapeutic potential beyond Pepaxti.

Financial momentum Strong first-quarter revenue growth in 2026 and a recent rights issue signaling ongoing financing to support expansion and late-stage development, offering a narrative for timing partnerships aligned with capital deployment and market access initiatives.

Strategic partnerships Existing and recent partnerships, such as the Salus distribution agreement, indicate a proven path for channel-driven sales in diverse regions, suggesting targeted outreach to distributors and regional pharma players could accelerate Pepaxti adoption.

Management continuity Leadership continuity with Jakob Lindberg in senior advisory roles and prior leadership positions may facilitate ongoing strategic alliances and sponsor-ready collaboration discussions, reducing negotiation risk for new partners.